Phenotypes associated with this allele
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm4(Wnt7b)Flng mutation
(0 available);
any
Gt(ROSA)26Sor mutation
(942 available)
Tg(Runx2-rtTA*M2)#Flng mutation
(0 available)
Tg(tetO-cre)1Jaw mutation
(5 available)
|
|
|
skeleton
|
|
• after doxycycline treatment
|
|
|
• in the long bones after doxycycline treatment
|
|
|
• proximal tibial trabecular bone volume/total volume is increased 6.6 fold at 2 months of age after doxycycline treatment
|
|
|
• markedly increased after doxycycline treatment
|
|
|
• marked increase in the trabecular bone mass in both primary and secondary ossification centers
|
|
|
• increased bone formation after doxycycline treatment
|
immune system
|
|
• after doxycycline treatment
|
hematopoietic system
|
|
• after doxycycline treatment
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm4(Wnt7b)Flng mutation
(0 available);
any
Gt(ROSA)26Sor mutation
(942 available)
Rptortm1Rueg mutation
(1 available);
any
Rptor mutation
(115 available)
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc mutation
(2 available)
|
|
|
skeleton
|
|
• when cre expression is suppressed by doxycycline treatment until 1 month of age then stopped, 3 weeks later bone mass is reduced compared to mutant mice with one wild-type Rptor allele
|
|
|
• when cre expression is suppressed by doxycycline treatment until 1 month of age then stopped, 3 weeks later bone marrow cavity is larger than in mutant mice with one wild-type Rptor allele but still smaller than in controls not over expressing Wnt7b
|
|
|
• when cre expression is suppressed by doxycycline treatment until 1 month of age then stopped, 3 weeks later osteoblast number is increased
• however, unlike in mice with one wild-type Rptor osteoblast hyperactivity is reduced
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm4(Wnt7b)Flng mutation
(0 available);
any
Gt(ROSA)26Sor mutation
(942 available)
Rptortm1Rueg mutation
(1 available);
any
Rptor mutation
(115 available)
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc mutation
(2 available)
|
|
|
skeleton
|
|
• when cre expression is suppressed by doxycycline treatment until 1 month of age the marrow cavity is decreased
|
|
|
• when cre expression is suppressed by doxycycline treatment until 1 month of age mice show very high bone mass 3 weeks after stopping doxycycline treatment
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm4(Wnt7b)Flng mutation
(0 available);
any
Gt(ROSA)26Sor mutation
(942 available)
Tg(Sp7-tTA,tetO-EGFP/cre)1Amc mutation
(2 available)
|
|
|
skeleton
|
|
• at E16.5 display a much thicker bone collar and no bone marrow
|
|
|
• at E16.5 the marrow region is occupied by cells that appear to be preosteoblasts and no marrow cavity is formed
• at E18.5 the marrow region is populated by mature osteoblasts
|
|
|
• profoundly dense bones throughout the body at 2 months of age
|
|
|
• at E18.5 the marrow region is populated by mature osteoblasts
|
|
|
• at E18.5 and 2 months of age
• when cre expression is suppressed by doxycycline treatment until 1 month of age mice show a profound high bone mass phenotype at 2 months of age
|
|
|
• slight delay in chondrocyte maturation at E14.5
|
|
|
| Find Mice |
Using the International Mouse Strain Resource (IMSR)
Mouse lines carrying:
Gt(ROSA)26Sortm4(Wnt7b)Flng mutation
(0 available);
any
Gt(ROSA)26Sor mutation
(942 available)
Tg(Col1a1-cre)1Ack mutation
(0 available)
|
|
|
skeleton
|
|
• proximal tibial trabecular bone volume/total volume is increased 13.7 fold and 5.1 fold at 2 months and 6 months of age, respectively
• by 9 months of age bone mass of the proximal tibial trabecular area is 30% less than controls
|
|
|
• osteoclast number per bone surface and percentage of bone resorption surface are reduced at 2 months of age
|
|
|
• absence of a marrow space in the long bones due to complete ossification
|
|
|
• profoundly dense bones in both males and females throughout the body at 2 months of age
• increased density persists at 6 months of age but is partially resolved at 9 months of age
|
|
|
• by 9 months of age bone mass of the proximal tibial trabecular area is 30% less than controls
• however, bone mass remains increased in the distal tibia and femur at 9 months of age
|
|
|
• proximal tibial trabecular bone volume/total volume is increased 13.7 fold and 5.1 fold at 2 months and 6 months of age, respectively
|
|
|
• excessive osteoblasts in the presumptive marrow cavity at E18.5
• increased osteoblast number normalized to bone surface at 2 months of age
• however, the density of osteocytes is similar to controls
|
|
|
• excessive bone occupies both primary and secondary ossification centers but the growth plate remains largely normal
• increased bone mass is seen at E18.5 and at 2 and 6 months of age
|
|
|
• mineral apposition rate, the percentage of mineralizing surface, and bone formation rate are all increased in the humerus
|
|
|
• increase in the serum levels of C-terminal telopeptide of type I collagen (a degradation product of type I collagen released upon bone resorption) at 1 and 9 months of age but not at 2 months of age
|
homeostasis/metabolism
hematopoietic system
|
|
• consistent with extramedullary hematopoiesis
|
|
|
• osteoclast number per bone surface and percentage of bone resorption surface are reduced at 2 months of age
|
immune system
|
|
• consistent with extramedullary hematopoiesis
|
|
|
• osteoclast number per bone surface and percentage of bone resorption surface are reduced at 2 months of age
|
limbs/digits/tail
|
|
• proximal tibial trabecular bone volume/total volume is increased 13.7 fold and 5.1 fold at 2 months and 6 months of age, respectively
• by 9 months of age bone mass of the proximal tibial trabecular area is 30% less than controls
|
growth/size/body
|
|
• consistent with extramedullary hematopoiesis
|
Analysis Tools